• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Purple Biotech Announces Poster Presentation at EACR 2025 on its Novel CAPTN-3 Tri-Specific Antibody Platform

    6/4/25 7:00:00 AM ET
    $PPBT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PPBT alert in real time by email

    REHOVOT, Israel, June 04, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced a poster presentation on its novel CAPTN-3 tri-specific antibody platform, will be featured at the Annual Congress of the European Association for Cancer Research (EACR) 2025, being held in Lisbon, Portugal from June 16 – 19, 2025.

    EACR poster details are as follows:

    Abstract #: EACR25-1964

    Title: "CAPTN-3: A novel platform of conditionally activated T cell and NK cell engagers"

    Session Title: Immunotherapy

    Session Date and Time: June 17, 2025, from 10:45 to 20:00

    Presenting Author: Dr. Hadas Reuveni, Vice President of R&D, Purple Biotech

    Abstracts related to the EACR meeting will be published online following the presentation. For more information, please visit the EACR 2025 website.

    About Purple Biotech

    Purple Biotech Ltd. (NASDAQ/TASE: PPBT) is a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance. The Company's oncology pipeline includes CM24, NT219, and CAPTN-3. CM24 is a humanized monoclonal antibody that blocks CEACAM1, which supports tumor immune evasion and survival through multiple pathways. CEACAM1 on tumor cells, immune cells and neutrophils extracellular traps is a novel target for the treatment of multiple cancer indications. As proof of concept of these novel pathways, the Company completed a Phase 2 study for the treatment of pancreatic ductal adenocarcinoma (PDAC) with CM24 as a combination therapy with the anti-PD-1 checkpoint inhibitor nivolumab and chemotherapy, demonstrating clear and consistent improvement across all efficacy endpoints and the identification of two potential serum biomarkers. NT219 is a dual inhibitor, novel small molecule that simultaneously targets IRS1/2 and STAT3. A Phase 1 dose escalation study was concluded as a monotherapy and in combination with cetuximab, in which NT219 demonstrated anti-tumor activity in combination with cetuximab in second-line patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). The Company is advancing NT219 into a Phase 2 study in collaboration with the University of Colorado, to treat R/M SCCHN patients in combination with cetuximab or pembrolizumab. The Company is advancing CAPTN-3, a preclinical platform of conditionally activated tri-specific antibodies, which engage both T cells and NK cells to induce a strong, localized immune response within the tumor microenvironment. The cleavable capping technology confines the compound's therapeutic activity to the local tumor microenvironment, thereby potentially increasing the anticipated therapeutic window in patients. The third arm specifically targets the Tumor Associated Antigen (TAA). The technology presents a novel mechanism of action by unleashing both innate and adaptive immune systems to mount an optimal anti-tumoral immune response. IM1240 is the first tri-specific antibody in development that targets the 5T4 antigen, which is expressed in a variety of solid tumors and is associated with advanced disease, increased invasiveness, and poor clinical outcomes. The Company's corporate headquarters are located in Rehovot, Israel. For more information, please visit https://purple-biotech.com/.

    CONTACTS:

    Company Contact:

    [email protected]



    Primary Logo

    Get the next $PPBT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PPBT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PPBT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Purple Biotech Announces Poster Presentation at EACR 2025 on its Novel CAPTN-3 Tri-Specific Antibody Platform

      REHOVOT, Israel, June 04, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced a poster presentation on its novel CAPTN-3 tri-specific antibody platform, will be featured at the Annual Congress of the European Association for Cancer Research (EACR) 2025, being held in Lisbon, Portugal from June 16 – 19, 2025. EACR poster details are as follows: Abstract #: EACR25-1964Title: "CAPTN-3: A novel platform of conditionally activated T cell and NK cell engagers"Session Title: ImmunotherapySession Date and T

      6/4/25 7:00:00 AM ET
      $PPBT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Purple Biotech Reports First Quarter 2025 Financial Results

      Final CM24 Phase 2 data presented at AACR Annual Meeting 2025, strengthening patient selection strategy for CM24 Phase 2b study planned to be initiated in Second Half of 2025 NT219 data presented at AACR Annual Meeting 2025; NT219 Phase 2 study in head and neck cancer on track to be initiated in First Half of 2025 CAPTN-3 differentiated T-cells and NK cells engagers tri-specific platform advances toward first-in-human clinical trials REHOVOT, Israel, May 21, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, annou

      5/21/25 7:10:40 AM ET
      $PPBT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Purple Biotech Appoints Shai Lankry as Chief Financial Officer

      U.S.-based Lankry brings over 20 years of financial leadership in biotech and healthcare with a proven track record of driving strategic growth, operational excellence, and capital market execution, including leading a U.S. IPO and M&A transaction REHOVOT, Israel, May 12, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, announced today the appointment of Shai Lankry as its Chief Financial Officer. "We are pleased to welcome Shai on board. His extensive experience in the U.S. and European biotech and pharma marke

      5/12/25 7:30:00 AM ET
      $GMDA
      $LPTX
      $PPBT
      $WST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Medical/Dental Instruments

    $PPBT
    Leadership Updates

    Live Leadership Updates

    See more
    • Purple Biotech Reports First Quarter 2025 Financial Results

      Final CM24 Phase 2 data presented at AACR Annual Meeting 2025, strengthening patient selection strategy for CM24 Phase 2b study planned to be initiated in Second Half of 2025 NT219 data presented at AACR Annual Meeting 2025; NT219 Phase 2 study in head and neck cancer on track to be initiated in First Half of 2025 CAPTN-3 differentiated T-cells and NK cells engagers tri-specific platform advances toward first-in-human clinical trials REHOVOT, Israel, May 21, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, annou

      5/21/25 7:10:40 AM ET
      $PPBT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors

      Dr. Margolin brings 35 years of expertise in biotechnology, pharma, and venture capital Purple Biotech also announces the resignation of Mr. Fabien Sebille, who served as the Company's Chief Business Officer REHOVOT, Israel, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced the appointment of Dr. Yael Margolin as an independent member of the Company's Board of Directors. Dr. Yael Margolin has more than 35 years of experience as senior manager, c

      12/20/23 8:05:00 AM ET
      $GMDA
      $PNT
      $PPBT
      $SCNI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Purple Biotech Reports Temporary Medical Leave of CEO Gil Efron

      Board of Directors appoints Isaac Israel, Board member and former CEO, as acting CEOCompany's business plan and clinical development programs continue as planned REHOVOT, Israel, March 24, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies that harness the power of the tumor microenvironment (TME) to overcome tumor immune evasion and drug resistance, today announced that the CEO, Gil Efron, has been hospitalized following an accident and will be on medical leave that is expected to last several months while he undergoes rehabilitation to recover from h

      3/24/23 7:00:00 AM ET
      $PPBT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PPBT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Purple Biotech Ltd.

      SC 13G/A - PURPLE BIOTECH LTD. (0001614744) (Subject)

      11/14/24 5:21:29 PM ET
      $PPBT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Purple Biotech Ltd.

      SC 13G - PURPLE BIOTECH LTD. (0001614744) (Subject)

      2/14/24 3:49:16 PM ET
      $PPBT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Purple Biotech Ltd. (Amendment)

      SC 13G/A - PURPLE BIOTECH LTD. (0001614744) (Subject)

      4/9/21 4:34:41 PM ET
      $PPBT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PPBT
    SEC Filings

    See more
    • SEC Form 6-K filed by Purple Biotech Ltd.

      6-K - PURPLE BIOTECH LTD. (0001614744) (Filer)

      5/21/25 7:12:52 AM ET
      $PPBT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Purple Biotech Ltd.

      6-K - PURPLE BIOTECH LTD. (0001614744) (Filer)

      5/12/25 7:30:10 AM ET
      $PPBT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Purple Biotech Ltd.

      6-K - PURPLE BIOTECH LTD. (0001614744) (Filer)

      5/6/25 4:00:47 PM ET
      $PPBT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PPBT
    Financials

    Live finance-specific insights

    See more
    • Purple Biotech Reports Fourth Quarter and Full-Year 2022 Financial Results

      Expands pipeline with acquisition of new tri-specific antibodies Data readouts for two lead clinical programs expected in 2023 REHOVOT, Israel, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced financial results for the year and the three months ended December 31, 2022. "We are reporting our 2022 financial results which are in line with our plans," said Gil Efron, Chief Executive Officer of Purple Biotech. "Our end-of-y

      2/8/23 7:12:00 AM ET
      $PPBT
      Biotechnology: Pharmaceutical Preparations
      Health Care